Award
NIH Reporter #3P30CA134274-18S4
Tumor Immunology and Immunotherapy Program
Recipient
University of Maryland Baltimore
Award Amount
$179,423.00
Ceiling
$179,423.00
Awarded
August 20, 2026
Identifier
3P30CA134274-18S4
Award to University of Maryland Baltimore for the Tumor Immunology and Immunotherapy Program, focusing on developing immune-based cancer treatments through innovative research and clinical trials.
Description
The Tumor Immunology and Immunotherapy (TII) Program is an interdisciplinary initiative focused on innovative basic science research and translational/clinical trials. The program aims to develop immune-based strategies for monitoring and treating cancer, with research focuses on cell-based and regulatory pathway-targeted immunotherapies, immune regulation calibration, and the roles of infection and inflammation in cancer development. The program includes 35 members conducting cancer-focused research supported by approximately $16.6 million annually.